Insilico Medicine
Insilico Medicine (HKEX: 03696) is a publicly traded Aging Drug Discovery company founded in 2014 and based in Hong Kong, Hong Kong.
Founded in 2014 by Alex Zhavoronkov and headquartered in Hong Kong and New York, Insilico Medicine is a clinical-stage biotech that uses generative AI to discover novel targets and design drug candidates end to end, from biology and chemistry through clinical-trial analysis. The company frames its mission around extending human productive longevity and has long maintained a Longevity advisory presence, applying its Pharma.AI platform across aging-related and other disease areas. Insilico listed on the Hong Kong Stock Exchange on December 30, 2025 (ticker 03696), raising roughly $293M in 2025's largest Hong Kong biotech IPO, with cornerstone investors including Eli Lilly and Tencent. It had previously raised over $500M across private rounds.
Brings industrial-scale generative AI to drug discovery and is the first AI-driven biotech to go public on HKEX's main board, with an explicit longevity framing.
insilico.com ↗·Aging Drug Discovery·
Hong Kong·public · HKEX: 03696 
